Loading patent…
OwnerJeffrey R. Stinson, Hing Wong +3inventors
InventorsJeffrey R. Stinson, Hing Wong, Alison D. O'Brien, Clare K. Schmitt, Angela Melton-Celsa
Estimating the term…
The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.
1-30. (canceled)
A pharmaceutical composition comprising a first humanized monoclonal antibody that specifically binds to Shiga toxin type 2 (Stx2) antigen and a second humanized monoclonal antibody that specifically binds to Shiga toxin type 1 (Stx 1) antigen, wherein the first antibody comprises a variable region consisting of the immunoglobulin heavy chain and light chain variable regions as set forth in SEQ ID NOs:
A pharmaceutical composition comprising a first humanized monoclonal antibody that specifically binds to Stx1 antigen and a second humanized monoclonal antibody that specifically binds to Stx2 antigen, wherein the variable region of the first monoclonal antibody comprises a human immunoglobulin constant region and a variable region, wherein said variable region consists of the murine 13C4 (ATCC Accession No. CRL 1794) heavy chain and light chain variable regions and wherein the variable region of the second monoclonal antibody comprises a human immunoglobulin constant region and a variable region, wherein said variable region consists of the murine 11E10 (ATCC Accession No. CRL 1907) heavy chain and light chain variable regions.
Dependencies are inferred from the claim text.